[go: up one dir, main page]

MA47816A - Composition pharmaceutique comprenant du sélexipag - Google Patents

Composition pharmaceutique comprenant du sélexipag

Info

Publication number
MA47816A
MA47816A MA047816A MA47816A MA47816A MA 47816 A MA47816 A MA 47816A MA 047816 A MA047816 A MA 047816A MA 47816 A MA47816 A MA 47816A MA 47816 A MA47816 A MA 47816A
Authority
MA
Morocco
Prior art keywords
selexipag
pharmaceutical composition
composition consisting
pharmaceutical
composition
Prior art date
Application number
MA047816A
Other languages
English (en)
Inventor
Klaus Hellerbrand
Alexandra Schlicker-Spain
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61655736&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA47816(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA47816A publication Critical patent/MA47816A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA047816A 2017-03-08 2018-03-07 Composition pharmaceutique comprenant du sélexipag MA47816A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2017055406 2017-03-08

Publications (1)

Publication Number Publication Date
MA47816A true MA47816A (fr) 2020-01-15

Family

ID=61655736

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047816A MA47816A (fr) 2017-03-08 2018-03-07 Composition pharmaceutique comprenant du sélexipag

Country Status (27)

Country Link
US (1) US12121516B2 (fr)
EP (1) EP3592391B1 (fr)
JP (1) JP6964679B2 (fr)
KR (1) KR102593075B1 (fr)
CN (1) CN110430900B (fr)
AR (1) AR111570A1 (fr)
AU (1) AU2018229750B2 (fr)
BR (1) BR112019018420A2 (fr)
CA (1) CA3055010A1 (fr)
CL (1) CL2019002511A1 (fr)
CO (1) CO2019009221A2 (fr)
CR (1) CR20190455A (fr)
DO (1) DOP2019000250A (fr)
EA (1) EA201992074A1 (fr)
EC (1) ECSP19072294A (fr)
ES (1) ES2880009T3 (fr)
IL (1) IL269061A (fr)
JO (1) JOP20190204A1 (fr)
MA (1) MA47816A (fr)
MX (1) MX2019010598A (fr)
NI (1) NI201900090A (fr)
PE (1) PE20191492A1 (fr)
PH (1) PH12019502033A1 (fr)
PL (1) PL3592391T3 (fr)
SG (1) SG11201907804QA (fr)
TW (1) TWI764996B (fr)
WO (1) WO2018162527A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3965767A1 (fr) * 2019-05-06 2022-03-16 Actelion Pharmaceuticals Ltd Méthodes de traitement de l'hypertension pulmonaire associée à la sarcoïdose
WO2020249602A1 (fr) * 2019-06-11 2020-12-17 Actelion Pharmaceuticals Ltd Procédés de traitement de l'hypertension artérielle pulmonaire
CA3154802A1 (fr) 2019-10-23 2021-04-29 Marc Patrik SCHRADER Composition pharmaceutique comprenant du selexipag
WO2021152060A1 (fr) 2020-01-31 2021-08-05 Actelion Pharmaceuticals Ltd Composition de sélexipag à libération contrôlée
TW202239408A (zh) * 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡𠯤衍生物的醫藥組成物
WO2022215045A1 (fr) * 2021-04-08 2022-10-13 Glenmark Pharmaceutical Limited Composition lyophilisée comprenant du sélexipag
WO2023131608A1 (fr) 2022-01-04 2023-07-13 Actelion Pharmaceuticals Ltd Compositions à libération contrôlée
WO2023209731A1 (fr) * 2022-04-25 2023-11-02 Msn Laboratories Private Limited, R&D Center Formes posologiques injectables liquides ou lyophilisées de sélexipag et leur procédé de préparation
WO2023214059A1 (fr) 2022-05-06 2023-11-09 Actelion Pharmaceuticals Ltd Composés de diphénylpyrazine utilisés en tant que promédicaments
TW202404594A (zh) * 2022-06-10 2024-02-01 日商日本新藥股份有限公司 醫藥組合物
WO2024017964A1 (fr) 2022-07-20 2024-01-25 Actelion Pharmaceuticals Ltd Composition pharmaceutique injectable comprenant un dérivé de diphénylpyrazine
WO2024133620A1 (fr) 2022-12-22 2024-06-27 Actelion Pharmaceuticals Ltd Test de dissolution in vitro
TW202444370A (zh) 2023-03-23 2024-11-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡衍生物之醫藥組成物
WO2025009945A1 (fr) * 2023-07-06 2025-01-09 재단법인대구경북과학기술원 Composition pharmaceutique pour la prévention ou le traitement de maladies cérébrales dégénératives comprenant du sélexipag

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI316055B (fr) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
AU2003213142B2 (en) * 2002-02-22 2005-11-10 Merck Sharp & Dohme Llc Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same
WO2009107736A1 (fr) 2008-02-28 2009-09-03 日本新薬株式会社 Inhibiteur de fibrose
WO2009154246A1 (fr) 2008-06-19 2009-12-23 日本新薬株式会社 Agent thérapeutique pour un dysfonctionnement érectile
CA2728089C (fr) 2008-06-23 2017-04-11 Nippon Shinyaku Co., Ltd. Agent therapeutique pour la stenose du canal spinal
WO2009157397A1 (fr) 2008-06-23 2009-12-30 日本新薬株式会社 Agent thérapeutique pour une lésion au tractus intestinal accompagnant l’administration d’un anti-inflammatoire nonstéroïdien
EP2289518B1 (fr) 2008-06-23 2016-11-02 Nippon Shinyaku Co., Ltd. Agent thérapeutique pour une affection abdominale inflammatoire
SI2447254T1 (en) 2009-06-26 2018-03-30 Nippon Shinyaku Co., Ltd. KRISTALI
WO2011024874A1 (fr) 2009-08-26 2011-03-03 日本新薬株式会社 Sels d'addition avec une base
US20140044797A1 (en) * 2011-04-19 2014-02-13 Rigshospitalet Prostacyclin and analogs thereof administered during surgery for prevention and treatment of capillary leakage
AU2012296953B2 (en) 2011-08-12 2016-10-20 Ascendis Pharma A/S Sustained release composition of prostacyclin
JP6400479B2 (ja) 2012-10-29 2018-10-03 株式会社カルディオ 肺疾患特異的治療剤
IL312865B1 (en) 2013-09-11 2025-02-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-reducing agents
GB201400412D0 (en) * 2014-01-10 2014-02-26 Heart Biotech Ltd Pharmaceutical formulations for the treatment of pulmonary arterial hypertension
WO2017029594A1 (fr) 2015-08-17 2017-02-23 Dr. Reddy's Laboratories Limited Procédés de préparation de selexipag et de sa forme amorphe
WO2017040872A1 (fr) * 2015-09-03 2017-03-09 Teva Pharmaceuticals International Gmbh Formes à l'état solide de selexipag
MX2018006343A (es) 2015-12-02 2018-08-01 Nippon Shinyaku Co Ltd Composicion farmaceutica que contiene 2-{4-[n-(5,6-difenilpirazin- 2-il)-n-isopropilamino]butiloxi}-n-(metilsulfonil)acetamida.
EP3192502A1 (fr) 2016-01-15 2017-07-19 Sandoz Ag Composition pharmaceutique de selexipag

Also Published As

Publication number Publication date
BR112019018420A2 (pt) 2020-04-14
NI201900090A (es) 2020-03-11
KR102593075B1 (ko) 2023-10-23
TWI764996B (zh) 2022-05-21
US20200129506A1 (en) 2020-04-30
JOP20190204A1 (ar) 2019-09-05
AR111570A1 (es) 2019-07-31
CA3055010A1 (fr) 2018-09-13
AU2018229750B2 (en) 2023-11-23
MX2019010598A (es) 2019-10-15
PE20191492A1 (es) 2019-10-21
PL3592391T3 (pl) 2021-11-02
AU2018229750A1 (en) 2019-09-12
DOP2019000250A (es) 2020-09-15
IL269061A (en) 2019-11-28
EP3592391A1 (fr) 2020-01-15
JP2020509070A (ja) 2020-03-26
TW201842910A (zh) 2018-12-16
US12121516B2 (en) 2024-10-22
KR20190122803A (ko) 2019-10-30
CR20190455A (es) 2019-11-12
ECSP19072294A (es) 2019-11-30
PH12019502033A1 (en) 2020-06-15
EP3592391B1 (fr) 2021-04-21
CN110430900B (zh) 2023-09-19
SG11201907804QA (en) 2019-09-27
JP6964679B2 (ja) 2021-11-10
CO2019009221A2 (es) 2019-08-30
WO2018162527A1 (fr) 2018-09-13
ES2880009T3 (es) 2021-11-23
CL2019002511A1 (es) 2020-01-17
EA201992074A1 (ru) 2020-02-27
CN110430900A (zh) 2019-11-08

Similar Documents

Publication Publication Date Title
MA47816A (fr) Composition pharmaceutique comprenant du sélexipag
EP3817722A4 (fr) Compositions pharmaceutiques comprenant du méloxicam
EP3565550A4 (fr) Compositions pharmaceutiques contenant du méloxicam
EP3548000A4 (fr) Compositions pharmaceutiques d'atropine
EP3325016C0 (fr) Composition pharmaceutique comprenant un vecteur adrenoviral
EP3621621A4 (fr) Compositions pharmaceutiques contenant du méloxicam
EP3256138A4 (fr) Compositions pharmaceutiques contenant du méloxicam
EP3454899C0 (fr) Composition pharmaceutique
DK3529248T3 (da) Farmaceutiske sammensætninger
MA46334A (fr) Composition pharmaceutique liquide
EP3452075A4 (fr) Composition pharmaceutique ophtalmique
EP3476386C0 (fr) Composition pharmaceutique liquide
EP3412660A4 (fr) Dérivé de sulfonamide et composition pharmaceutique le contenant
LT3655038T (lt) Farmacinė kompozicija
MA43705A (fr) Formulation pharmaceutique
EP3364944C0 (fr) Compositions pharmaceutiques d'il-2
LT3116491T (lt) Terapiškai aktyvių junginių farmacinės kompozicijos
EP3250367A4 (fr) Étalonnage d'agent
DK3532029T3 (da) Flydende farmaceutisk sammensætning
DK3634377T3 (da) Farmaceutisk formulering
MA47516A (fr) Composition pharmaceutique
EP3542821A4 (fr) MOLÉCULE INDUISANT LA DÉGRADATION DE p53 ET COMPOSITION PHARMACEUTIQUE
MA49837A (fr) Compositions pharmaceutiques
EP3360547A4 (fr) Composition pharmaceutique bactéricide et virucide
DK3672631T5 (da) Farmaceutiske sammensætninger indeholdende anti-beta-amyloid-antistoffer